Earnings History Data for Axsome Therapeutics, Inc. (AXSM) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing novel therapies for the management of pain and other central nervous system disorders. Its product candidate portfolio consists of AXS-02 and AXS-05 which are in clinical trial stage. Axsome Therapeutics, Inc. is based in New York.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
05-05-2025	PM		AXSM	Axsome Therapeutics, Inc.	5,470	-0.80	-1.26	-1.09	Axsome Therapeutics GAAP EPS of -$1.22 beats by $0.13, revenue of $121.5M beats by $2.22M [5/5/2025 7:07 AM]	116.60	4.39 (3.91%)	118.00	5.79 (5.16%)	64.11 - 139.13	818,656	630,000	3,318
Axsome Therapeutics GAAP EPS of -$1.22 beats by $0.13, revenue of $121.5M beats by $2.22M [5/5/2025 7:07 AM] Axsome targets FDA decision on AXS-14 for fibromyalgia in Q2 2025 [5/5/2025 11:45 AM] Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update [2025-05-05 07:00AM]
18-02-2025	PM		AXSM	Axsome Therapeutics	6,382	-0.96	-1.00	0.00	Axsome Therapeutics GAAP EPS of -$1.54 misses by $0.53, revenue of $118.77M beats by $0.94M [2/18/2025 7:03 AM]	128.15	-3.00 (-2.29%)	124.63	-6.52 (-4.97%)	64.11 - 134.18	1,347,753	1,310,000	15,164
Axsome Therapeutics GAAP EPS of -$1.54 misses by $0.53, revenue of $118.77M beats by $0.94M [2/18/2025 7:03 AM] Axsome Therapeutics targets multiple NDA submissions and pipeline advancements through 2025 [2/18/2025 11:14 AM] Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update [2025-02-18 07:00AM]
12-11-2024	PM		AXSM	Axsome Therapeutics, Inc.	4,320	-1.34	-1.38	-1.32	Axsome Therapeutics GAAP EPS of -$1.34 beats by $0.07, revenue of $104.76M beats by $6.69M [11/12/2024 7:02 AM]	99.55	8.56 (9.41%)	94.50	3.52 (3.87%)	55.02 - 101.50	1,466,258	420,000	10,810
Axsome Therapeutics Q3 2024 Earnings Preview [11/11/2024 1:08 PM] Axsome Therapeutics GAAP EPS of -$1.34 beats by $0.07, revenue of $104.76M beats by $6.69M [11/12/2024 7:02 AM] Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update [2024-11-12 07:00AM]
05-08-2024	PM		AXSM	Axsome Therapeutics, Inc.	4,090	-1.24	-1.30	1.00	Axsome Therapeutics GAAP EPS of -$1.67 misses by $0.34, revenue of $87.2M beats by $0.27M [8/5/2024 7:01 AM]	83.18	-1.24 (-1.47%)	75.01	-9.41 (-11.15%)	55.02 - 98.40	766,594	530,000	4,233
Axsome Therapeutics GAAP EPS of -$1.67 misses by $0.34, revenue of $87.2M beats by $0.27M [8/5/2024 7:01 AM] Earnings summary: Axsome Therapeutics Q2 net product revenue grows 87% Y/Y [8/5/2024 7:14 AM]
06-05-2024	PM		AXSM	Axsome Therapeutics, Inc.	3,510	-1.09	-1.20	-0.22	Axsome Therapeutics GAAP EPS of -$1.44 misses by $0.21, revenue of $75M beats by $2.15M [5/6/2024 7:01 AM]	75.86	1.06 (1.42%)	74.75	-0.05 (-0.07%)	55.02 - 98.40	726,095	500,000	5,712
Axsome Therapeutics GAAP EPS of -$1.44 misses by $0.21, revenue of $75M beats by $2.15M [5/6/2024 7:01 AM]
20-02-2024	PM		AXSM	Axsome Therapeutics, Inc.	4,420	-0.73	-1.21	-1.28	Axsome Therapeutics GAAP EPS of -$2.08 misses by $0.92, revenue of $71.53M beats by $2.49M [2/20/2024 7:10 AM]	81.42	-11.39 (-12.28%)	85.40	-7.41 (-7.98%)	53.71 - 98.40	2,824,374	560,000	28,315
Axsome Therapeutics GAAP EPS of -$2.08 misses by $0.92, revenue of $71.53M beats by $2.49M [2/20/2024 7:10 AM]
06-11-2023	PM		AXSM	Axsome Therapeutics, Inc.	3,040	-1.32	-1.24	-1.03	Axsome Therapeutics GAAP EPS of -$1.32 misses by $0.09, revenue of $57.79M beats by $2.93M [11/6/2023 7:02 AM]	62.50	-2.64 (-4.05%)	62.42	-0.08 (-0.13%)	49.60 - 91.29	1,211,820	680,000	2,522
Axsome Therapeutics GAAP EPS of -$1.32 misses by $0.09, revenue of $57.79M beats by $2.93M [11/6/2023 7:02 AM]
07-08-2023	PM		AXSM	Axsome Therapeutics, Inc.	3,280	-1.00	-1.24	-1.06	Axsome Therapeutics GAAP EPS of -$1.54 misses by $0.30, revenue of $46.01M beats by $5.06M [8/7/2023 7:01 AM]	71.09	-2.57 (-3.49%)	75.25	1.59 (2.16%)	38.87 - 91.29	1,754,395	750,000	55,908
Axsome Therapeutics GAAP EPS of -$1.54 misses by $0.30, revenue of $46.7M beats by $5.75M [8/7/2023 7:01 AM]
08-05-2023	PM	7:00 AM ET (May 8)	AXSM	Axsome Therapeutics, Inc.	3,100	-0.22	-1.13	-1.03	Axsome TherapeuticsEPS of -$0.26, revenue of $94.6M beats by $69.12M [5/8/2023 7:03 AM]	77.20	3.46 (4.69%)	77.65	3.91 (5.30%)	20.63 - 82.85	2,626,732	570,000	58,020
Axsome TherapeuticsEPS of -$0.26, revenue of $94.6M beats by $69.12M [5/8/2023 7:03 AM] Axsome gains after Q1 results for newly launched depression therapy [5/8/2023 9:28 AM]
27-02-2023	PM	7:00 AM ET (Feb 27)	AXSM	Axsome Therapeutics, Inc.	2,720	-1.28	-1.18	-0.90	Axsome Therapeutics GAAP EPS of -$1.41 misses by $0.28, revenue of $24.37M beats by $2.49M [2/27/2023 7:02 AM]	64.06	3.02 (4.94%)	63.80	2.75 (4.50%)	20.63 - 82.00	1,468,166	930,000	42,181
Axsome Therapeutics GAAP EPS of -$1.41 misses by $0.28, revenue of $24.37M beats by $2.49M [2/27/2023 7:02 AM] Axsome hits snag on Alzheimer's agitation candidate as FDA wants more safety data [2/27/2023 2:58 PM]
07-11-2022	PM	7:00 AM ET (Nov 7)	AXSM	Axsome Therapeutics, Inc.	2,590	-1.03	-1.10	-0.93	Axsome Therapeutics GAAP EPS of -$1.07 beats by $0.02, revenue of $16.8M misses by $0.26M [11/7/2022 7:03 AM]	56.76	-0.33 (-0.58%)	54.53	-2.56 (-4.48%)	20.63 - 71.98	1,022,832	1,530,000	23,010
Axsome Therapeutics GAAP EPS of -$1.07 beats by $0.02, revenue of $16.8M misses by $0.26M [11/7/2022 7:03 AM] Is a Surprise Coming for Axsome (AXSM) This Earnings Season? [Nov-04-22 08:30AM] 3 Top Healthcare Stocks to Buy for November [Nov-04-22 06:00AM] Axsome Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update [Nov-07-22 07:00AM]
09-08-2022	PM	7:05 AM ET (Aug 9)	AXSM	Axsome Therapeutics, Inc.	1,570	-1.06	-1.19	-0.86	Axsome Therapeutics GAAP EPS of -$1.06 beats by $0.18, revenue of $8.81M beats by $2.52M [8/9/2022 7:03 AM]	44.98	1.67 (3.86%)	40.20	-3.11 (-7.18%)	19.38 - 47.49	1,473,885	710,000	53,317
Axsome Therapeutics Q2 2022 Earnings Preview [8/8/2022 1:54 PM] Axsome Therapeutics GAAP EPS of -$1.06 beats by $0.18, revenue of $8.81M beats by $2.52M [8/9/2022 7:03 AM] Axsome posts 2Q beat; FDA action on depression therapy expected in Q3 [8/9/2022 9:12 AM] Axsome Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update [Aug-09-22 07:00AM] Drug, Biotech Stocks' Q2 Earnings on Aug 9: EXEL, BHC & More [Aug-08-22 09:14AM]
02-05-2022	PM	7:00 AM ET (May 2)	AXSM	Axsome Therapeutics, Inc.	1,250	-1.03	-1.02	-0.78	Axsome Therapeutics GAAP EPS of -$1.03 misses by $0.03 [5/2/2022 7:09 AM]	34.09	2.34 (7.38%)	31.59	-0.16 (-0.50%)	19.38 - 74.10	1,129,801	2,420,000	81,599
Axsome Therapeutics GAAP EPS of -$1.03 misses by $0.03 [5/2/2022 7:09 AM] Axsome stock falls as FDA rejects migraine therapy AXS-07; Q1 net loss widens Y/Y [5/2/2022 8:02 AM] Axsome Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update [May-02-22 07:05AM] Axsome Therapeutics Receives FDA Complete Response Letter for New Drug Application for AXS-07 for the Acute Treatment of Migraine [May-02-22 07:00AM] As Expected, FDA Rejects Axsome Therapeutics' Migraine Candidate [May-02-22 09:20AM] Axsome Therapeutics (AXSM) Q1 2022 Earnings Call Transcript [May-02-22 03:00PM]
01-03-2022	PM	7:00 AM ET (Mar 1)	AXSM	Axsome Therapeutics, Inc.	1,060	-0.90	-0.99	-0.78	Axsome Therapeutics GAAP EPS of -$0.90 beats by $0.08 [3/1/2022 7:03 AM]	30.85	2.74 (9.75%)	28.24	0.13 (0.46%)	19.38 - 74.10	1,315,397	620,000	93,587
Axsome Therapeutics Q4 2021 Earnings Preview [2/28/2022 12:22 PM] Axsome Therapeutics GAAP EPS of -$0.90 beats by $0.08 [3/1/2022 7:03 AM] Axsome stock rises 9% as company eyes potential approval/launch of drugs in FY22 [3/1/2022 11:28 AM] Drug/Biotech Stocks' Q4 Earnings on Mar 1: PRGO, JAZZ & More [Feb-28-22 10:00AM] Axsome Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update [Mar-01-22 07:00AM] This Stock Could Soar by 195%, According to Wall Street [Mar-01-22 10:23AM] Why Axsome Therapeutics Stock Is Bolting Higher Today [Mar-01-22 02:13PM]
08-11-2021	PM	7:05 AM ET (Nov 8)	AXSM	Axsome Therapeutics, Inc.	1,540	-0.93	-0.94	-0.58	Axsome Therapeutics EPS beats by $0.03 [11/8/2021 7:03 AM]	43.35	3.15 (7.84%)	39.27	-0.93 (-2.31%)	19.38 - 87.24	1,558,082	620,000	153,436
Axsome Therapeutics EPS beats by $0.03 [11/8/2021 7:03 AM] Axsome shares up 10% premarket following Q3 2021 earnings beat [11/8/2021 8:35 AM] Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update [Nov-08-21 07:00AM] Why Axsome Therapeutics Stock Is Rising Today [Nov-08-21 12:37PM] Axsome Therapeutics, inc (AXSM) Q3 2021 Earnings Call Transcript [Nov-08-21 05:30PM]
09-08-2021	PM	7:00 AM ET (Aug 9)	AXSM	Axsome Therapeutics, Inc.	1,830	-0.86	-0.88	-0.49	Axsome Therapeutics EPS beats by $0.07 [8/9/2021 7:05 AM]	27.36	-23.80 (-46.52%)	33.10	-18.06 (-35.30%)	27.30 - 90.00	9,128,010	340,000	1,558,545
Axsome Therapeutics EPS beats by $0.07 [8/9/2021 7:05 AM] Axsome stock tanks 45% on likely delay in potential approval of AXS-05; depression study meets endpoints [8/9/2021 7:36 AM] Axsome Therapeutics Announces AXS-05 Achieves Primary and Key Secondary Endpoints in the MERIT Phase 2 Trial in Treatment Resistant Depression [Aug-09-21 07:00AM] Axsome Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update [Aug-09-21 07:05AM] Axsome Therapeutics (AXSM) Sees Hammer Chart Pattern: Time to Buy? [Aug-09-21 06:07AM] Why Axsome Therapeutics Stock Is Crashing Today [Aug-09-21 11:28AM] AXSOME THERAPEUTICS INVESTIGATION: Block & Leviton Investigates Axsome Therapeutics For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm [Aug-09-21 12:54PM] AXSM ALERT - Shareholder Rights Firm Labaton Sucharow is Investigating Axsome Therapeutics, Inc. (NASDAQ:AXSM) for Potential Securities Violations and Breach of Fiduciary Duty [Aug-09-21 01:10PM] INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors With Losses to Contact the Firm [Aug-09-21 07:31PM] AXSM INVESTOR ALERT: Rosen Law Firm Encourages Axsome Therapeutics, Inc. Investors with Losses to Inquire About Class Action Investigation AXSM [Aug-09-21 04:37PM]
10-05-2021	PM	7:00 AM ET (May 10)	AXSM	Axsome Therapeutics, Inc.	2,310	-0.78	-0.83	-0.88	Axsome Therapeutics EPS beats by $0.04 [5/10/2021 7:05 AM]	54.04	-2.92 (-5.13%)	58.64	1.68 (2.95%)	50.05 - 94.06	320,297	590,000	644
Axsome Therapeutics EPS beats by $0.04 [5/10/2021 7:05 AM] Axsome shares rise on Q1 results, cash position update [5/10/2021 8:11 AM] Why Earnings Season Could Be Great for Axsome Therapeutics (AXSM) [May-07-21 08:44AM] Axsome Therapeutics Joins Mental Health America and other Advocacy Organizations in Raising Awareness and Providing Support for Mental Health During Mental Health Month [May-07-21 07:00AM] Axsome Therapeutics, Inc. to Host Earnings Call [May-10-21 06:15AM] Axsome Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update [May-10-21 07:00AM] Axsome Therapeutics, Inc. (AXSM) Q1 2021 Earnings Call Transcript [May-10-21 05:30PM]
01-03-2021	PM	7:00 AM ET (Mar 1)	AXSM	Axsome Therapeutics, Inc.	2,700	-0.78	-0.73	-0.71	Axsome Therapeutics EPS misses by $0.08 [3/1/2021 7:02 AM]	69.09	1.73 (2.57%)	67.36	0.0 (0.00%)	35.44 - 109.53	415,318	293,066	8,519
Axsome Therapeutics EPS misses by $0.08 [3/1/2021 7:02 AM] Axsome Therapeutics reports 2020 as year of significant accomplishments [3/1/2021 10:33 AM] Axsome Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update [Mar-01-21 07:00AM] Axsome Therapeutics, Inc. to Host Earnings Call [Mar-01-21 06:30AM]
05-11-2020	PM	7:05 AM ET (Nov 5)	AXSM	Axsome Therapeutics, Inc.	2,590	-0.58	-0.58	-0.56	Axsome Therapeutics EPS misses by $0.03 [11/5/2020 7:18 AM]	69.51	-5.22 (-6.99%)	69.51	0.0 (0.00%)	20.48 - 109.94	569,460	271,759	3,154

10-08-2020	PM	7:00 AM ET (Aug 10)	AXSM	Axsome Therapeutics, Inc.	2,890	-0.49	-0.54	-0.41	Axsome Therapeutics EPS beats by $0.12 [8/10/2020 7:08 AM]	82.11	4.04 (5.17%)	80.96	2.89 (3.70%)	13.64 - 109.94	277,507	373,825	3,162